Because GM-CSF/Sargramostim has been safely and routinely used as a subcutaneous injection treatment and, off-label, as an inhalation treatment, we suggest that this long-FDA-approved drug should be tested for its ability to improve recovery in COVID-19 patients and/or after resolution of infection in severe ARDS survivors to ameliorate potential cognitive deficits. This evidence concerns the gene CSF2 and COVID-19.